Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 6.3% Higher – Here’s Why

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) traded up 6.3% during mid-day trading on Wednesday . The stock traded as high as $11.48 and last traded at $11.45. 45,696 shares changed hands during trading, a decline of 86% from the average session volume of 327,551 shares. The stock had previously closed at $10.77.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on YMAB. Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Morgan Stanley dropped their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Tuesday, August 13th. BMO Capital Markets cut their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Y-mAbs Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $21.38.

Y-mAbs Therapeutics Trading Up 10.1 %

The company has a market capitalization of $531.20 million, a PE ratio of -21.20 and a beta of 0.68. The business’s 50-day simple moving average is $13.57 and its two-hundred day simple moving average is $12.82.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter last year, the firm posted ($0.18) EPS. On average, analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares in the company, valued at $877,822.57. The trade was a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics during the third quarter valued at approximately $44,000. China Universal Asset Management Co. Ltd. boosted its position in Y-mAbs Therapeutics by 66.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the period. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics during the 3rd quarter worth $133,000. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics in the third quarter worth $178,000. Finally, Empire Financial Management Company LLC bought a new stake in Y-mAbs Therapeutics in the third quarter valued at $210,000. 70.85% of the stock is owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.